|
1
|
Grönberg H: Prostate cancer epidemiology.
Lancet. 361:859–864. 2003.PubMed/NCBI
|
|
2
|
Sivonova MK, Dobrota D, Matakova T, et al:
Microsomal epoxide hydrolase polymorphisms, cigarette smoking and
prostate cancer risk in the Slovak population. Neoplasma. 59:79–84.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Khan N, Adhami VM and Mukhtar H: Apoptosis
by dietary agents for prevention and treatment of prostate cancer.
Endocr Relat Cancer. 17:39–52. 2010. View Article : Google Scholar
|
|
4
|
Gartel AL and Tyner AL: The role of the
cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer
Ther. 1:639–649. 2002.PubMed/NCBI
|
|
5
|
Liu S, Bishop WR and Liu M: Differential
effects of cell cycle regulatory protein p21(WAF1/Cip1) on
apoptosis and sensitivity to cancer chemotherapy. Drug Resist
Updat. 6:183–195. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Suzuki H, Ito R, Ikeda K and Tamura TA:
TATA-binding protein (TBP)-like protein is required for
p53-dependent transcriptional activation of an upstream promoter of
the p21Waf1/Cip1 gene. J Biol Chem. 282:19792–19803. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Englert C, Maheswaran S, Garvin AJ,
Kreidberg J and Haber DA: Induction of p21 by the Wilms' tumor
suppressor gene WT1. Cancer Res. 57:1429–1434. 1997.
|
|
8
|
Deng C, Zhang P, Harper JW, Elledge SJ and
Leder P: Mice lacking p21CIP1/WAF1 undergo normal development, but
are defective in G1 checkpoint control. Cell. 82:675–684. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gartel AL: The conflicting roles of the
cdk inhibitor p21(CIP1/WAF1) in apoptosis. Leuk Res. 29:1237–1238.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
El-Deiry WS, Tokino T, Velculescu VE, et
al: WAF1, a potential mediator of p53 tumor suppression. Cell.
75:817–825. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ma H, Zhou Z, Wei S and Wei Q: Association
between p21 Ser31Arg polymorphism and cancer risk: a meta-analysis.
Chin J Cancer. 30:254–263. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gravina S, Lescai F, Hurteau G, et al:
Identification of single nucleotide polymorphisms in the p21
(CDKN1A) gene and correlations with longevity in the Italian
population. Aging (Albany NY). 1:470–480. 2009.PubMed/NCBI
|
|
13
|
Keshava C, Frye BL, Wolff MS, McCanlies EC
and Weston A: Waf-1 (p21) and p53 polymorphisms in breast cancer.
Cancer Epidemiol Biomarkers Prev. 11:127–130. 2002.PubMed/NCBI
|
|
14
|
Liu F, Li B, Wei Y, et al: P21 codon 31
polymorphism associated with cancer among white people: evidence
from a meta-analysis involving 78,074 subjects. Mutagenesis.
26:513–521. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li G, Liu Z, Sturgis EM, et al: Genetic
polymorphisms of p21 are associated with risk of squamous cell
carcinoma of the head and neck. Carcinogenesis. 26:1596–1602. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Taghavi N, Biramijamal F, Abbaszadegan MR,
Khademi H, Sotoudeh M and Khoshbakht S: P21(waf1/cip1) gene
polymorphisms and possible interaction with cigarette smoking in
esophageal squamous cell carcinoma in northeastern Iran: a
preliminary study. Arch Iran Med. 13:235–242. 2010.PubMed/NCBI
|
|
17
|
Lin G, Fang F, Yu XJ and Yu L:
Meta-analysis of the relationship between p21 Ser31Arg polymorphism
and lung cancer susceptibility. Genet Mol Res. 10:2449–2456. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shirai O, Ohmiya N, Taguchi A, et al: P53,
p21, and p73 gene polymorphisms in gastric carcinoma.
Hepatogastroenterology. 57:1595–1601. 2010.PubMed/NCBI
|
|
19
|
Ebner F, Schremmer-Danninger E and Rehbock
J: The role of TP53 and p21 gene polymorphisms in breast cancer
biology in a well specified and characterized German cohort. J
Cancer Res Clin Oncol. 136:1369–1375. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang W, Qi Q, Zhang H, et al: p21
Waf1/Cip1 polymorphisms and risk of esophageal cancer. Ann Surg
Oncol. 17:1453–1458. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang SP, Wu WJ, Chang WS, et al: p53
Codon 72 and p21 codon 31 polymorphisms in prostate cancer. Cancer
Epidemiol Biomarkers Prev. 13:2217–2224. 2004.PubMed/NCBI
|
|
22
|
Facher EA, Becich MJ, Deka A and Law JC:
Association between human cancer and two polymorphisms occurring
together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor
gene. Cancer. 79:2424–2429. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao X, Chen YQ, Wu N, et al: Somatic
mutations of the WAF1/CIP1 gene in primary prostate cancer.
Oncogene. 11:1395–1398. 1995.PubMed/NCBI
|
|
24
|
Kibel AS, Suarez BK, Belani J, et al:
CDKN1A and CDKN1B polymorphisms and risk of advanced prostate
carcinoma. Cancer Res. 63:2033–2036. 2003.PubMed/NCBI
|
|
25
|
Wang Z, Sturgis EM, Zhang F, et al:
Genetic variants of p27 and p21 as predictors for risk of second
primary malignancy in patients with index squamous cell carcinoma
of head and neck. Mol Cancer. 11:172012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rastinejad F and Blau HM: Genetic
complementation reveals a novel regulatory role for 3′ untranslated
regions in growth and differentiation. Cell. 72:903–917. 1993.
|
|
27
|
Valentin MD, Canalle R, Queiroz Rde P and
Tone LG: Frequency of polymorphisms and protein expression of
cyclin-dependent kinase inhibitor 1A (CDKN1A) in central nervous
system tumors. Sao Paulo Med J. 127:288–294. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sivonová M, Waczulíková I, Dobrota D, et
al: Polymorphisms of glutathione-S-transferase M1, T1, P1 and the
risk of prostate cancer: a case-control study. J Exp Clin Cancer
Res. 28:322009.PubMed/NCBI
|
|
29
|
Lei D, Sturgis EM, Liu Z, Zafereo ME, Wei
Q and Li G: Genetic polymorphisms of p21 and risk of second primary
malignancy in patients with index squamous cell carcinoma of the
head and neck. Carcinogenesis. 31:222–227. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Aaltomaa S, Lipponen P, Eskelinen M,
Ala-Opas M and Kosma VM: Prognostic value and expression of
p21(waf1/cip1) protein in prostate cancer. Prostate. 39:8–15. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Baretton GB, Klenk U, Diebold J, Schmeller
N and Lohrs U: Proliferation and apoptosis-associated factors in
advanced prostatic carcinomas before and after androgen deprivation
therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J
Cancer. 80:546–555. 1999. View Article : Google Scholar
|
|
32
|
Omar EA, Behlouli H, Chevalier S and
Aprikian AG: Relationship of p21(WAF-I) protein expression with
prognosis in advanced prostate cancer treated by androgen ablation.
Prostate. 49:191–199. 2001. View Article : Google Scholar : PubMed/NCBI
|
